

Elanco

TYLAN(R) 200 INJECTION

TYLAN(R) 200 Injection

AH0206

TYLAN(R) 200 Injection (an antibiotic) is a tradename for a sterile solution of tylosin base with each ml containing 200 mg of tylosin activity (as the base). It is used in beef cattle and nonlactating dairy cattle for the treatment of bovine respiratory complex, diphtheria, foot rot, and metritis. It is used in swine for the treatment of swine arthritis, swine pneumonia, swine erysipelas, and acute swine dysentery.

I. MANUFACTURER/EMERGENCY INFORMATION

- A. MANUFACTURER: ELANCO PRODUCTS COMPANY
A DIVISION OF ELI LILLY AND COMPANY
LILLY CORPORATE CENTER
INDIANAPOLIS, INDIANA 46285
- B. EMERGENCY TELEPHONE NUMBERS:
ELI LILLY AND COMPANY (317) 276-2000
CHEMTREC (800) 424-9300
- C. GENERAL INFORMATION TELEPHONE NUMBER:
ELANCO ANIMAL HEALTH (317) 276-3000
- D. ISSUED: 9/80; REVISED: 10/86, 7/89

II. MATERIAL IDENTIFICATION

- A. GENERIC NAME: Tylosin (as the base) 20%
1. CHEMICAL ABSTRACT REGISTRY NUMBER (CAS#): 1401-69-0
- B. OTHER INGREDIENTS:
- | | |
|------------------|-----------|
| benzyl alcohol | 4.0% |
| propylene glycol | 50.0% |
| water | Q.S. 100% |

There are no hazardous or carcinogenic inert ingredients.

III. PHYSICAL AND CHEMICAL PROPERTIES

- A. NORMAL PHYSICAL STATE, ODOR, APPEARANCE: Colorless to light brown transparent liquid. Has a faint, sweet odor.
- B. BOILING POINT: 212 deg F (100 deg C)
- C. pH (aqueous 50/50): 8.0 to 9.5
- D. SOLUBILITY IN WATER: Miscible with water.
- E. MELTING POINT: Not applicable.

IV. FIRE AND EXPLOSION HAZARD DATA

- A. AUTO-IGNITION TEMPERATURE: 779 deg F (412 deg C)
- B. FLASHPOINT: Not applicable
- C. EXPLOSIVE LIMIT:
- LOWER EXPLOSIVE LIMIT (LEL): No ignition up to 10.2% by volume in air.
 - UPPER EXPLOSIVE LIMIT (UEL): Not established.
- D. UNUSUAL FIRE AND EXPLOSION HAZARDS: None known.
- E. FIRE FIGHTING INFORMATION: This is an aqueous solution and will not burn. If involved in a fire, extinguish with water.

V. NATIONAL FIRE PROTECTION ASSOCIATION (NFPA 704)

(4 = Extreme; 3 = High; 2 = Moderate; 1 = Slight;
0 = Insignificant)

- A. HEALTH: 0
- B. FLAMMABILITY: 1
- C. REACTIVITY: 0

VI. SHIPPING REQUIREMENTS

- A. DOT HAZARD CLASS: Not regulated.

VII. REACTIVITY DATA

- A. STABILITY AND STORAGE: Store at 72 deg F (22 deg C) or below. Product should not be used after the date printed on the container. A dating of 24 months is noted on the container.
- B. HAZARDOUS DECOMPOSITION: None known.
- C. HAZARDOUS POLYMERIZATION: None known.
- D. INCOMPATIBILITY: None known.

VIII. HEALTH HAZARD DATA

- A. TOXICOLOGY (Animal Toxicity Data):
- ACUTE EXPOSURE (TYLAN 200 Injection):
 - EYES: Rabbit, slight irritant.
 - SKIN: Rabbit, 2.0 ml/kg, no deaths or toxicity, slight irritant.
 - INHALATION: Rat, 1.05 mg total formulation/L for one hour, no deaths, colored secretion around eyes.
 - INGESTION: Rat, 0.5 ml/kg. no deaths or toxicity.
 - SENSITIZATION: Guinea pig, sensitizer (Tylosin tartrate).
 - CHRONIC EXPOSURE (tylosin base): The following effects were reported in chronic, teratogenic, and reproductive toxicity studies in laboratory animals where experimental dosage levels and durations of exposure were far in excess of those likely to occur in humans.
 - CHRONIC TOXICITY: Salivation, diarrhea, and vomiting after repeated large oral doses.
 - TERATOLOGY & REPRODUCTION: Not teratogenic. No impairment of reproductive capacity or adverse effects to offspring in 3 successive generations.
 - MUTAGENICITY: No applicable information.
 - CARCINOGENICITY: Not listed as a carcinogen or potential carcinogen by ACGIH, NCI/NTP, IARC, or OSHA. Not considered to be carcinogenic in lifetime feeding study conducted by Lilly.
- B. EFFECTS OF EXPOSURE: Based on laboratory animal studies that have been conducted with tylosin, Elanco Products Company and U.S. Government agencies have concluded that the use of tylosin does not present a hazard when recommended handling procedures are followed.
- SIGNS AND SYMPTOMS OF EXPOSURE: Accidental injection may cause pain and swelling at the site accompanied by anxiety. No lasting ill effects have been reported. Skin rashes, possibly on the basis of hypersensitivity, may occur. No symptoms resulted in the few cases of accidental ingestions reported. May be irritating to the eyes.
 - MEDICAL CONDITIONS GENERALLY AGGRAVATED BY EXPOSURE: No corroborative information is available that would establish the aggravation of a medical condition by exposure to TYLAN 200 Injection; however, it is a reasonable assumption that highly allergic individuals would be at somewhat greater risk for demonstrating an allergic reaction when exposed.
- C. EXPOSURE GUIDELINES*:
- Permissible Exposure Limit (PEL): Not established.
 - Threshold Limit Value (TLV): Not established.
- D. PRIMARY ROUTES OF ENTRY: Skin and inhalation.

Elanco

TYLAN(R) 200 INJECTION

 IX. FIRST AID (Statement of Practical Treatment)

- A. EYES: Flush eyes with plenty of water and call a physician if irritation persists.
- B. SKIN: Wash all exposed areas with plenty of soap and water. Wash all contaminated clothing before reuse. If irritation occurs and is severe or persistent, contact a physician.
- C. INHALATION: Exposure by this route is not anticipated.
- D. INGESTION: Do not induce vomiting. Call a physician or Poison Control Center. It is unlikely that toxicity would result unless a large amount was ingested.
- E. ACCIDENTAL INJECTION: For accidental injection no specific treatment is needed other than symptomatic. Treat wound if necessary and consider need for tetanus immunization.

 X. PRECAUTIONS FOR SAFE HANDLING AND USE

- A. SPILL HANDLING INFORMATION: Do not contaminate any body of water. Clean up spill using suitable absorbent material. Place it and damaged unusable containers in landfill in accordance with applicable regulations. Large spills due to traffic accidents, etc., should be reported immediately to CHEMTREC and Elanco Products Company for assistance. Prevent spilled material from flowing onto adjacent land or into streams, ponds or lakes.
- B. CONTAINER DISPOSAL: No special package disposal required.
- C. CAUTIONS: Allergenic and/or sensitizing to certain individuals. Avoid skin and eye contact. Do not mix TYLAN 200 Injection with other injectable solutions as this may cause precipitation of the active ingredients. Do not administer to horses or other equines. Injection of tylosin in equines has been fatal.
- D. STORAGE: (See Section VII, Paragraph A)

 XI. PROTECTIVE EQUIPMENT REQUIREMENTS

During manufacturing, wear goggles to protect eyes, wear impermeable gloves and protective equipment to avoid direct contact with skin. Use NIOSH(1) approved organic solvent respirator.

 XII. OTHER INFORMATION

- A. NADA NUMBER: 12-965
- B. REFERENCES:
 (1)NIOSH Certified Equipment Guide
- C. TYLAN(R) (tylosin, Elanco)
- D. NOTE: This information applies only to TYLAN 200 Injection which is sold in the U.S.

 All information contained herein is offered in good faith and with the belief that it is accurate. As of the date of issuance or revision, we are providing all information that we have or are aware of relevant to the anticipated use or handling of the material. However, in the event of an adverse incident associated with this material, this Material Safety Data Sheet is not, and is not intended to be, a substitute for consultation with appropriately trained personnel.

 DISCLAIMER OF EXPRESSED AND IMPLIED WARRANTIES: although preparer and owner have taken reasonable care in the preparation of this document, we extend no warranties and make no representation as to the accuracy or completeness of the information contained herein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequences of its use. Each user should make a determination as to the suitability of the information for their particular purpose(s). A request has been made to the manufacturer to approve the contents of this material safety data sheet. Upon receipt of any changes a new MSDS will be made available.

COMPAS Code: 3100090